Abpro and NJCTTQ agree terms for major I-O collaboration

Privately-held US-based biotech firm Abpro has entered into a collaboration with Chinese drugmaker NJCTTQ (Nanjing Zhengda Tianqing Pharmaceutical)  to develop multiple antibodies in immuno-oncology, including T-cell therapies.

The collaboration leverages Abpro’s DiversImmune antibody discovery platform. To date, the technology has generated antibodies for pharmaceutical and biotechnology companies against more than 300 unique targets.

The American firm is eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royalties.